Exelixis Was Three Months From an Answer. Then the FDA Hit Pause.

But there's a wrinkle. In patients without liver metastases (a specific subgroup), the survival advantage was less convincing: a hazard ratio of 0.83 with median survival of 15.9 months versus 12.7 months for regorafenib. That sounds decent, but it didn't reach statistical significance. Translation: the benefit looked real, but the math couldn't guarantee it wasn't a fluke.

This kind of mixed signal is exactly the sort of thing that makes the FDA want to take a closer look.

Why the FDA Is Playing It Careful

This delay fits into a broader pattern. The FDA has been tightening its standards for combination cancer drugs over the past year. In July 2025, the agency released draft guidance that essentially said: if you're combining two drugs, you need to prove each one is pulling its weight. You can't just show the combo works and call it a day. The agency wants evidence that each ingredient in the recipe matters.

For zanzalintinib plus atezolizumab, that's a reasonable question to ask. Atezolizumab is a checkpoint inhibitor (a type of immunotherapy that helps the immune system recognize and attack cancer cells). Zanzalintinib is a kinase inhibitor that targets tumor blood supply and signaling pathways. Together, they represent different attack strategies. But the FDA wants the receipts.

This isn't unique to Exelixis. Other oncology combos have faced similar scrutiny recently, with review extensions becoming more common when the data package raises even modest questions. The agency approved encorafenib plus cetuximab plus chemo for BRAF-mutant colorectal cancer earlier this year, but that combination had a cleaner data story.

Wall Street's Verdict: Shrug, With Anxiety

Exelixis' stock closed at $56.12 on September 11, the day before the announcement. That's actually above the average analyst price target of $53.69, which tells you something interesting: the market had already been pricing in optimism about the zanzalintinib launch.

The analyst consensus is mixed. MarketBeat shows a Hold rating with a $50.07 target (well below where the stock sits). MarketScreener reports an Outperform consensus from 20 analysts with an average target of $38.05, with a range from $29 to $45. That gap between where the stock trades and these targets reflects genuine uncertainty about how this FDA review will play out.

A three-month delay doesn't mean rejection. Plenty of drugs have received extensions and still gotten approved. But it does inject uncertainty into a story that investors were counting on for a clean, year-end catalyst.

The Bigger Picture: A Crowded Race

Even if zanzalintinib gets the green light in March 2027, Exelixis won't have the colorectal cancer field to itself. The treatment landscape is fragmenting rapidly along molecular lines. KRAS G12C inhibitors paired with EGFR antibodies are gaining ground. HER2-directed therapies and antibody-drug conjugates are advancing. Novel bispecific antibodies targeting both PD-1 and VEGF are chasing the holy grail of making immunotherapy work in MSS tumors (the majority of colorectal cancers where checkpoint inhibitors alone have largely failed).

The biggest unmet need in the space remains MSS/pMMR metastatic colorectal cancer, which accounts for most patients and responds poorly to existing immunotherapy. If zanzalintinib can carve out a meaningful survival benefit in later-line treatment, it still has a real market. But every month of delay is a month where competitors can close the gap.

What Happens Next

The new PDUFA date is March 3, 2027. Between now and then, watch for a few things. First, whether the FDA schedules an advisory committee meeting (that would signal the agency wants outside expert input, which can cut both ways). Second, whether Exelixis shares any additional data from STELLAR-303 at medical conferences this winter. And third, whether analysts start adjusting their models to account for the later launch timeline.

For Exelixis, this isn't a crisis. It's a speed bump. But in a therapeutic area this competitive, speed bumps have a way of mattering more than you'd think. The marathon continues; the finish line just moved a little further away.

J&J Just Locked Down a $5 Billion Drug Until 2035. Generics Can't Touch It.

A federal court just blocked generic Spravato until 2035, handing J&J a decade of exclusivity on a drug headed toward $5 billion in peak sales. For generics companies, the ruling is a costly warning shot.